This study investigated the presence of combined pathologies in a large cohort of autopsies that show a primary pathologic diagnosis of phosphorylated 43-kDa TAR DNA-binding protein (FTLD-TDP), the majority of which portrayed clinical phenotypes consistent with primary progressive aphasia or behavioral variant frontotemporal dementia (bvFTD). Thirty-eight cases with FTLD-TDP (30 type-A and 8 type-C) were identified to determine characteristic differences between cases with and without combined pathologies. Findings indicated that combined pathologies co-occur with FTLD-TDP type-A at a high frequency (50%)-greater than when compared to FTLD-TDP type-C cases (12.5%). Those with FTLD-TDP type-A and combined pathologies showed significantly longer lifespans (p < 0.05), and longer disease durations (p < 0.05), than those with only FTLD-TDP type-A. Cases with FTLD-TDP type-A and known genetic mutations tended not to show combined pathology. Those with the GRN mutation and FTLD-TDP type-A showed a significantly younger age of onset (p < 0.05) and younger age at death (p < 0.01) compared to noncarriers. In 1 bvFTD case, we highlight the rare presence of "triple" FTLD-TDP type-A, FTLD-tau, and Alzheimer pathology. The ante-and post-mortem features associated with combined pathologies in FTLD-related disorders are of useful consideration in the stratification of patients to drug trials, and in the development of therapeutic targets for FTLD.
INTRODUCTION
Recent investigations have shown that dementia syndromes are often not related to a single pathophysiologic process and, as a result, combined pathologies found during autopsy are common. There have been many reports of combined pathologies in the aging brain (1) (2) (3) (4) , particularly associated with the primary clinical diagnoses of dementia due to Alzheimer disease (AD), dementia with Lewy bodies, or vascular dementia. The clinical characterization of patients with combined pathologies, especially those presenting with atypical dementia syndromes, becomes particularly challenging as syndromes evolve with the spread of molecular pathology.
Primary progressive aphasia (PPA), as well as behavioral and mixed variants of frontotemporal dementia (FTD), can have at autopsy a heterogeneous array of pathologies, with the majority demonstrating frontotemporal lobar degeneration (FTLD) with either tau-positive (FTLD-tau), TDP-43-positive (FTLD-TDP), or more rarely, FUS-positive (FTLD-FUS) inclusions (5, 6) . A subpopulation of each clinical group displays AD pathology, with a rate of up to 40% in PPA cases (2) . In a prior study, we investigated 16 cases of clinical PPA and 10 cases of behavioral variant frontotemporal dementia (bvFTD) all with a primary pathologic diagnosis of AD, to determine whether their nonamnestic, language-or behaviorpredominant impairments reflected the presence of combined FTLD-TDP pathology; interestingly, FTLD-TDP pathology was found in only 3 cases of the total 26 PPA/FTD group, suggesting a weak link between combined FTLD-TDP pathology and clinical phenotypes of PPA and bvFTD, when the primary pathology is AD (7) .
Distinct "subtypes" of FTLD-TDP cases were determined based on the presence, predominance, and distribution of the various TDP-43-immunopositive neuronal cytoplasmic inclusions, neuronal intranuclear inclusions, and dystrophic neurites. Based on the Mackenzie et al. 2011 harmonized classification scheme, FTLD-TDP cases with moderate to numerous TDP-43-immunoreactive neuronal cytoplasmic inclusions (NCIs) and short dystrophic neurites predominantly in upper cortical layers are designated Type A, whereas cases that show predominantly long dystrophic neurites in upper layers with rare NCIs are designated Type C (8) . We chose to focus this study on FTLD-TDP types A and C, because these 2 subtypes have been strongly linked with PPA/FTD syndromes (6); in fact, FTLD-TDP type C is almost invariably associated with left hemispheric anterior temporal atrophy and the semantic variant of PPA (9) whereas FTLD-TDP type A is more heterogeneous and can be found in non-semantic PPA or behavioral variant FTD (disinhibited or amotivational subtypes) (10) . We omitted from this study FTLD-TDP type B, which pathologically shows predominantly NCIs distributed in all cortical layers, as it is often associated with amyotrophic lateral sclerosis (ALS).
The present study investigated the presence of multiple pathologies in a large cohort of autopsied cases that had a primary pathologic diagnosis of FTLD-TDP type A or type C, the majority of which portrayed clinical phenotypes consistent with PPA or FTD. Our findings suggest that combined pathologies appear to co-occur at a greater frequency in cases with type A versus type C FTLD-TDP. In 1 unique case, we highlight the presence of combined and severe FTLD-TDP type A, FTLD-tau, and AD pathology. A subsequent analysis explored the frequency of combined pathology in cases with versus without genetic mutations or risk variants. Finally, we discuss the implications of multiprotein deposits for the clinical diagnosis and stratification of patients in clinical trials targeted at TDP-43, should they become available in the future.
MATERIALS AND METHODS

Case Material and Neuropathologic Evaluation
The focus of this report is the presence of multiple pathologies in cases with TDP-proteinopathies that cause dementia; therefore, we restricted our cohort to those with FTLD-TDP type A and C pathology, and excluded FTLD-TDP type B pathology, as the latter is strongly associated with ALS. Thirty-eight cases with pathologic diagnoses of FTLD-TDP type A or type C were identified from the Northwestern University Alzheimer's Disease Center Brain Bank. The majority of participants were recruited through the Northwestern University PPA Research Program and the Neurobehavior and Memory Clinic of the Northwestern Medical Group. As such, our cohort was likely overrepresentative of individuals with PPA and bvFTD, reflective of the focus of the Center's central mission.
Thirty-five participants were confirmed to be righthanded, 1 was ambidextrous, and handedness was unknown in the remaining 2 participants. The PPA root diagnosis was based on the criteria of Mesulam (11, 12) (14) . Two other cases were shown to have a TMEM106B variant, a risk variant associated with FTLD-TDP pathology (15) . In 1 case diagnosed with PPA, a variant in the triggering receptor expressed on myeloid cells-2 (TREM2), R47H, was discovered; TREM2 has been shown to be associated with late-onset AD and, more recently, with the development of FTD (16) . Finally, 1 patient showed a TBK1 (encoding TANK-binding kinase 1) mutation, also shown to be closely tied to FTD (17) and ALS (18) .
Brain autopsies were performed by the Neuropathology Core of the Northwestern University Cognitive Neurology and Alzheimer's Disease Center, according to IRB-approved protocols. All brains were evaluated grossly for cortical, caudate, hippocampal, cerebellar, and brainstem atrophy, vascular pathology, and microscopically for AD, Lewy body, and vascular pathologies, and FTLD-tau, FTLD-TDP, FTLD-FUS, and Lewy and non-Lewy a-synucleinopathies. A case was considered to have "combined pathologies" if there was sufficient pathology present in >1 pathologic entity that either diagnosis alone could have been the explanation for the patient's cognitive deterioration.
Eighteen regions were investigated, including bilateral dorsolateral prefrontal cortex (BA 8-9), bilateral inferior frontal gyrus (Broca's area, BA 44), bilateral superior temporal gyrus (BA 22), bilateral inferior parietal lobule (BA 39), primary motor cortex (BA 4), primary visual cortex (BA 17), anterior cingulate gyrus (BA 24), striatum, basal ganglia with nucleus basalis of Meynert, thalamus with subthalamic nucleus, mammillary bodies, amygdala, anterior hippocampus with entorhinal cortex, posterior hippocampus, cerebellum with dentate nucleus, cerebellar vermis, midbrain, pons, and medulla.
Postmortem intervals (PMI) ranged from 4 to 31 hours, and brains were fixed in formalin or paraformaldehyde. Blocks of tissue from regions of interest were embedded in paraffin, cut at 5-mm thickness, and mounted on charged slides. For immunohistochemical stains, sections were deparaffinized in xylene and stained using the avidin-biotinperoxidase method. The Vecstastain Elite Kit (Vector Laboratories, Cat #PK 6100, Burlingame, CA) was utilized with streptavidin-or avidin-peroxidase, and amino ethylcarbazole (Biogenex, San Ramon, CA) or diaminobenzidine (Cat # 34065, Pierce-Endogen, Rockford, IL) as chromogen.
To assess AD pathology, specific antibodies to tau (AT8, Pierce-Endogen) and b-amyloid (4G8, Signet, Dedham, MA) were used to visualize neurofibrillary tangles and b-amyloid plaques, respectively. For evaluation of TDP-43 pathology, an antibody against TDP-43 phosphorylated at Ser409/ 410 (pS409-410-2, Cosmo Bio, Tokyo, Japan) was used. All brains were also evaluated for Lewy body pathology with a-synuclein antibody (LB509, Zymed-Invitrogen, Carlsbad, CA), and for non-Alzheimer-and non-Lewy-type deposits of tau, a-synuclein, and ubiquitin (DAKO polyclonal, DAKO, Carpinteria, CA) or p62 (p62Lck ligand, BD Biosciences, San Jose, CA).
Sections from each cortical area were also stained with 1.0% Thioflavin-S (Sigma-Aldrich), which recognizes b-pleated sheet protein conformations to visualize neurofibrillary tangles and mature/compact amyloid plaques. The Gallyas silver stain was used to confirm the presence of neurofibrillary tangles, and hematoxylin and eosin (H&E) was used to note obvious neuronal loss and astrocytosis, superficial microvacuolation and gliosis, Lewy bodies, and/or depopulation of pigmented nuclei.
Alzheimer disease pathology was staged according to NIA/AA criteria (19) . TDP-43 pathology was graded based on semiquantitative estimates in each region. The 3 common types of TDP-43 inclusions were distinguished: neuronal cytoplasmic inclusions, neuronal intranuclear inclusions, and dystrophic neurites. Densities were designated as "rare," "sparse," "moderate," or "frequent" based on previously established criteria (8) .
Genetics
A portion of samples were screened using targeted sequencing of a panel of genes previously implicated in neurodegenerative disorders, including the most common causative genes for Mendelian forms of AD and FTD (APP, TARDBP, FUS, GRN, MAPT, PSEN1, and PSEN2). Exonic regions for these genes were captured using a custom-designed library (SeqCap EZ Choice Library, NimbleGen) and sequenced on an Illumina HiSeq2500 sequencer at the UCLA Neuroscience Genomics Core (http://www.semel.ucla.edu/ungc). Sequence reads were mapped to the GRCh37/hg19 reference genome, variants were joint-called with GATK according to GATK Best Practices recommendations (20) and annotated using ANNOVAR (21) . All pathogenic variants identified were subsequently confirmed by Sanger sequencing. The presence of a pathological hexanucleotide repeat expansion in C9orf72 was detected using both fluorescent and repeat-primed PCR, as previously described (22) . Genotypes for TREM2 R47H (rs75932628) and APOE (rs429358 and rs7412) risk alleles were obtained using TaqMan SNP assays.
RESULTS
Cohort Characteristics of Cases With FTLD-TDP Type A With and Without Combined Pathology
Thirty individuals showed a postmortem diagnosis of FTLD-TDP type A; 15 of these 30 (50%) had significant combined pathology. Independent sample t-tests were used to determine differences in brain weight, PMI, age at onset and disease duration between those with and without combined pathology. Chi square tests were used to determine gender differences. Age at death was significantly higher by almost a decade in individuals with Type A with combined pathology (i.e. at least 2 comorbid pathologies) compared to those without (p < 0.05). Symptom duration was also significantly shorter in those without combined pathology (p < 0.05), suggesting a more aggressive disease process ( Table 1) .
The majority of cases with combined pathology showed hippocampal sclerosis (6 of 15), followed by high Alzheimer disease neuropathologic change (ADNC; 4 of 15). One of these 4 cases showed comorbid FTLD-tau pathology consistent with progressive supranuclear palsy; to our knowledge, this case is the first of its kind to show combined high ADNC, FTLD-TDP, and FTLD-tau-PSP. We highlight this case below. The remaining 5 cases showed combined vascular disease (1 of 15), motor neuron disease (2 of 15), or mammillary body atrophy (2 of 15). There were 2 cases of the total cohort (n ¼ 38) that had evidence of subclinical Lewy body disease, not sufficient for a pathologic diagnosis; 1 case had Lewy body disease in brainstem only and the other in the amygdala only.
Genotypes and Frequency of Combined Pathology
An independent sample t-test analysis was conducted between those with GRN mutations (GRNþ, n ¼ 13) and those without (GRNÀ, n ¼ 17 J
mutations. There were no significant differences between GRN groups in disease duration (p > 0.05). The frequency of GRNþ cases and combined pathology (3 of 13) was significantly lower than those who were GRNÀ (12 of 17; p < 0.05) ( Table 2) . Chi square (Fisher exact) statistical tests were used to determine differences in the frequency of combined pathology between individuals with and without known genetic mutations or risk variants. The frequency of individuals with a mutation (either associated with pathogenesis or increased risk) and only a single pathology (13 of 15; 10 with GRN; 1 with C9orf72, 1 with TMEM106B, 1 with TBK1) was significantly higher than those with a mutation and combined pathology (7 total, 3 GRN, 1 TREM2, 2 C9orf72, 1 TMEM106B) (p < 0.05), suggesting that combined pathology appears to be less common in those with known genetic mutations.
APOE genotype was available in 21 of 30 cases with TDP-43 type A. All 21 showed either APOE-e3,e3 or APOEe3,e4 and there were no significant differences in APOE-e4 frequency, a known risk factor for AD, between FTLD-TDP type A groups with versus without combined pathology.
Features of FTLD-TDP Type A Versus Type C
Eight of 38 cases showed FTLD-TDP type C pathology. There were no significant differences between brain weight, age of onset and age at death between individuals with FTLD-TDP type A compared to those with Type C (Table 3) ; symptom duration was significantly longer in Type C cases (M ¼ 11.6; SD ¼ 2.1) compared to Type A (M ¼ 7.2; SD ¼ 3.6) (p < 0.05). PMI was longer in the Type C group (p < 0.05) compared to the Type A group. There were no differences in APOE-e4 frequency in cases with FTLD-TDP type A compared to cases with FTLD-TDP type C (genotyping available in 7 of 8).
Differences in the frequency of combined pathology were examined using chi square statistical tests in individuals with postmortem FTLD-TDP type A versus FTLD-TDP type C. In those with Type A, 50% (15 of 30) showed combined pathology whereas only $13% (1 of 8) of Type C showed combined pathology; there was a trend towards statistical significance (p ¼ 0.056). The 1 FTLD-TDP type C case showing combined pathology had bilateral hippocampal sclerosis, and it is worth noting that no FTLD-TDP type C cases showed pathology consistent with Alzheimer disease (Table 3) .
Of the 30 individuals with pathologic diagnoses of FTLD-TDP type A, the majority (24 of 30 or 80%) had clinical diagnoses of PPA (n ¼ 12) or bvFTD (n ¼ 12). Most of those with the clinical diagnosis of FTD showed language impairment toward the end of life in addition to primary behavioral symptoms. The remaining 6 individuals had clinical diagnoses of probable AD (n ¼ 3), "normal" cognition (n ¼ 1), Lewy body dementia (n ¼ 1, pathology showed tertiary pigment spheroid degeneration and amygdala-only Lewy body degeneration), and 1 with "multidomain dementia". Three cases (2 bvFTD and 1 PPA) with FTLD-TDP type A showed additional symptoms consistent with corticobasal syndrome. Of the 8 cases with FTLD-TDP type C, 7 were diagnosed clinically with PPA; 1 had the clinical diagnosis of bvFTD with additional language symptoms.
"Triple" Pathologies in 73-Year-Old Patient With FTD
The patient was a 73-year-old right-handed woman who presented with 4 years of progressive changes in behavior, motivation, and language. She showed increased irritability and suspiciousness, and lost interest in typical activities and hobbies (i.e. writing Christmas cards and playing tennis). Medical history is notable for breast cancer; family history is remarkable for a son with glioblastoma. On examination, she was tearful and dysphoric and had difficulty sustaining her attention. She had executive dysfunction characterized by impaired set-shifting, perseverations, and impersistence. Spontaneous speech was nonfluent with frequent word-finding pauses. She showed difficulty naming objects and writing was severely impaired. Comprehension was preserved for single word objects, but impaired for grammatically complex sentences. Repetition was intact. Autobiographical memory for recent events was relatively preserved. She had no abnormal motor findings during the baseline evaluation. Brain MRI showed bilateral perisylvian atrophy, slightly greater on the left. FDG-PET showed bilateral frontal and anterior temporal hypometabolism (L > R), with some additional left-sided parietal hypometabolism (Fig. 1) . Her clinical phenotype was consistent with bvFTD, based on the earliest and most predominant symptoms, with mixed behavioral and aphasic components. During the 7-year follow-up period, memory became impaired and language and behavioral symptoms progressed; speech became unintelligible with no sign of comprehension ability, and she became highly aggressive. In the year leading up to death, she displayed gait abnormality, bilateral tremor, and falls that caused multiple fractures. She died at the age of 80 after an 11-year disease course. At autopsy, the brain weight was 1124 g. There was severe bilateral atrophy in frontal and temporal lobes and moderate atrophy in parietal and occipital lobes, with the atrophy slightly greater in the left hemisphere. These patterns were consistent with imaging findings performed 6 years prior to death. There was also moderate atrophy in the caudate and hippocampus, and severe ventricular dilatation (Fig. 2) . Amyloid deposits were present in the neocortex, hippocampus, basal ganglia, substantia nigra, and cerebellum, consistent with Thal amyloid phase 5 (19) . There were high densities of tangles in entorhinal cortex, hippocampus (CA1), prefrontal cortex, superior temporal gyrus, and parietal cortex, all greater in left than right hemisphere. Density of tangles was slightly greater in parietal than in frontal or temporal cortices (Fig. 3A, B) .
TDP-43 immunohistochemistry revealed NCIs, NIIs and short dystrophic neurites in the neocortex, dentate gyrus of the hippocampus, and striatum, with inclusions being most dense in superficial neocortical layer II consistent with FTLD-TDP type A pathology. TDP-43 inclusions were greater on the left in temporal and parietal language-related regions, suggesting a correlation with aphasic symptoms. NCIs were also present in the substantia nigra. There were no TDP-43-positive inclusions in the hypoglossal nucleus. Tau immunostains of these inclusions were negative, while p62 immunohistochemistry highlighted both FTLD-TDP and AD pathology (Fig. 3C, D) .
AT8 immunohistochemistry revealed neuronal tangles and tufted astrocytes in the caudate, putamen, and globus pallidus, that were positive for 4R tau and negative for 3R tau, consistent with progressive supranuclear palsy (PSP). The PSP-type tau pathology in this case affected primarily the basal ganglia and brainstem and appeared not to involve the cortex (Fig. 4) . Given the relative sparing of cortex, it is possible that tau pathology gave rise to late-onset motor symptoms. This case also showed mild cerebrovascular disease and pigment-spheroid degeneration in the substantia nigra and globus pallidus, not likely sufficient to contribute to the patient's cognitive phenotype.
DISCUSSION
This investigation is the first to describe a high frequency (50%) of combined pathology in cases with FTLD-TDP type A. The majority of these cases had antemortem diagnoses consistent with PPA or bvFTD, but there were 6 cases that showed other clinical phenotypes, highlighting the notion that there is no one-to-one correlation between clinical phenotype and pathology, single or combined. Our initial findings show that those with FTLD-TDP type A and combined pathology tend to show longer lifespans and longer disease durations than those with "pure" FTLD-TDP without combined pathology. The appearance of combined neurodegenerative diseases in older age is not an uncommon observation (23) . It is, however, considered less usual for combined pathologies to present in patients with younger onset clinical dementia syndromes. These early onset dementia syndromes typically manifest with phenotypes that are largely amnestic, leading to a pathologic diagnosis of typical Alzheimer disease. In a large clinicopathologic study, Josephs and colleagues (24) showed that 57% of brains with postmortem AD show TDP-43 pathology in medial temporal regions including amygdala, but the large majority of cases in this cohort were diagnosed antemortem with amnestic dementias. We have shown previously that the most significant predictor of TDP-43 pathology in typical amnestic dementia is hippocampal sclerosis, although the mechanistic relationship between these 2 disease processes remains largely unknown (7) . In our current sample of individuals with underlying FTLD-TDP type A pathology, the most common type of combined pathology was also hippocampal sclerosis, found in 40% of this cohort. Hippocampal sclerosis is quite common in FTLD-TDP; although the reason for this is currently not clear, it should be noted that both pathologies share common genetic risk factors, including for example, TMEM106B (25) . Two patients showed comorbid mammillary atrophy. Though not fully understood, atrophy to this region may be due to trans-synaptic neuronal degeneration of the mammillary bodies secondary to atrophy of limbic-related structures that lie along the Papez circuit (CA1, entorhinal cortex, and subiculum as observed in 1 of the 2 cases). We did not find evidence of Lewy body disease sufficient for a pathologic diagnosis in any of the cases.
Our second major finding showed that additional pathology is not common in those with known genetic mutations or risk variants. Cases that did show a specific GRN mutation and FTLD-TDP type A had a younger age of onset and a younger age at death compared to noncarriers. These findings, in tandem, may reflect tight mechanistic links between GRN haploinsufficiency, neuronal accumulation of TDP-43, and the severity of disease spread (26) .
FTLD-TDP type C, characterized by a predominance of long dystrophic neurites (27) is rare and often associated with the semantic subtype of PPA (28) and anterior temporal atrophy. Our cases (7 of 8 with PPA) with FTLD-TDP type C did not tend to show combined pathology; only 1 of 8 cases showed hippocampal sclerosis. The observation that FTLD-TDP type C dystrophic neurites and AD-type neurofibrillary tangles do not appear to comingle, and show distinct predilections for focal brain regions, highlight the complex principles of selective vulnerability.
We highlight 1 patient who presented with a bvFTD syndrome characterized by mixed behavioral and aphasic features, and who showed "triple" pathology of AD, PSP, and FTLD-TDP type A. There have been only a few cases reported with FTLD-TDP and PSP comorbidity (29, 30) but none that also showed postmortem AD. This patient's atypical phenotype and evolving clinical course stresses the potential gainand/or loss-of-function that is often seen when multiple proteinopathies coexist. A multimodal approach for imaging is most desirable for these classes of patients with complex, atypical clinical symptoms. Unfortunately, CSF and PET biomarkers were not available in this patient during clinical evaluation, but would have been helpful to determine contribution of putative amyloid and tau burden. Focal patterns of cortical atrophy appeared to be concordant with deficits, though it was clearly not possible to have predicted the type and nature of pathology. This fascinating case, harboring 3 distinct classes of neurodegenerative pathology, highlights the wellestablished observation that clinical syndromes and atrophy arise as a result of the anatomic distribution of pathology, rather than its cellular nature (2, 31) .
Findings from this study indicate that combined FTLD-TDP pathology is not restricted to AD. There have been prior reports of comorbid AD pathology and FTLD-TDP type A (7) and FTLD-TDP type C (32); in 1 study, FTLD-TDP type C pathology was observed in a patient with the semantic variant of PPA who showed positive in vivo biomarkers for AD and mild AD pathology at autopsy (i.e. a score of A3, B1, C1 according to the NIA-AA guidelines for the neuropathological assessment of AD). This example, in combination with our reported findings of combined FTLD-TDP pathology, suggests that caution is warranted when interpreting positive AD biomarkers in individuals with atypical clinical dementia syndromes, such as PPA or bvFTD. In these syndromes that are defined by progressive decline and emerging clinical symptoms, the assessment of multiprotein deposits is especially critical for the determination of clinicopathologic correlations. While the mechanisms of FTLD-TDP misregulation and propagation are unknown, the high percentage of overlapping pathologic findings in FTLD-related disorders is a worthwhile consideration in the development of new drug targets and therapeutic interventions. Animal models that account for combined pathology, and TDP-43-specific imaging ligands-once available-will allow for a more nuanced examination of the temporal spread of pathology, and can help identify causal links between FTLD-TDP and neurodegeneration.
